---
document_datetime: 2026-02-20 16:38:22
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/dawnzera-epar-all-authorised-presentations_en.pdf
document_name: dawnzera-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8940232
conversion_datetime: 2026-02-21 12:38:57.015444
docling_version:
  docling-serve: 1.13.0
  docling-jobkit: 1.11.0
  docling: 2.74.0
  docling-core: 2.65.1
  docling-ibm-models: 3.11.0
  docling-parse: 5.3.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.3-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form    | Route of Administration   | Immediate Packaging                           | Content (concentration)   | Pack size         |
|------------------|-------------------|------------|------------------------|---------------------------|-----------------------------------------------|---------------------------|-------------------|
| EU/1/25/2001/001 | Dawnzera          | 80 mg      | Solution for injection | Subcutaneous use          | pre-filled syringe (glass) in pre- filled pen | 0.8 ml (100 mg/ml)        | 1 pre-filled pen  |
| EU/1/25/2001/002 | Dawnzera          | 80 mg      | Solution for injection | Subcutaneous use          | pre-filled syringe (glass) in pre- filled pen | 0.8 ml (100 mg/ml)        | 3 pre-filled pens |